V.A. Parfenov, A.A. Naumenko, I.S. Preobrazhenskaya

Department of Nervous Diseases and Neurosurgery SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMPH, Moscow
The article considers the modern principles of management of patients with Alzheimer's disease. Medical and drug-free methods used in the treatment of cognitive, emotional and behavioral disorders are discussed. The data on the effectiveness of the basic symptomatic therapy: N-methyl D-aspartate receptor antagonists, acetylcholine esterase inhibitors as monotherapy and in combination with choline alfoscerate – are presented. Some of the issues of the use and effectiveness of cognitive-motor training, psychosocial support to patients with cognitive impairment, their relatives and caregivers are highlighted.


  1. Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. Ремедиум. 2014;1:106.
  2. Парфенов В.А. Профилактика болезни Альцгеймера. Журнал неврологии, нейропсихиатрии и психосоматики. 2011;3:8–12.
  3. Morris M. C., Evans D. A., Tangney C.C., Bienias J.L., Wilson R.S. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006;67:1370–376.
  4. Del Parigi A., Panza F., Capurso C., Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin. 2006;69:1–19.
  5. Bayer-Carter J.L.1, Green P.S., Montine T.J., VanFossen B., Baker L.D., Watson G.S., Bonner L.M., Callaghan M., Leverenz J.B., Walter B.K., Tsai E., Plymate S.R., Postupna N., Wilkinson C.W., Zhang J., Lampe J., Kahn S.E., Craft S. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch. Neurol. 2011;68(6):743–52.
  6. Larrieu S, Letenneur L, Helmer C, Dartigues J.F., Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J. Nutr. Health Aging. 2004;8:150–54.
  7. Wilson R.S., Scherr P.A., Schneider J.A., Tang Y., Bennett D.A. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007;69:1911–920.
  8. Barnes D.E., Blackwell T., Stone K.L., Goldman S.E., Hillier T., Yaffe K. Study of Osteoporotic Fractures.Cognition in older women: the importance of daytime movement. J. Am. Geriatr. Society. 2008;56:1658–664.
  9. Schmidt, W., Endres, M., Dimeo, F., Jungehulsing, G.J. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc. Dis. 2013;35(4):303–12.
  10. Colcombe, S., Kramer, A.F. Fitness effects on the cognitive function of older adults a meta-analytic study. Psycholog. Sci. 2003;14(2):125–30.
  11. Gates N., Fiatarone Singh M.A., Sachdev P.S., Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am. J. Geriatric Psychiatry. 2013;21(11):1086–097.
  12. Barnes D.E., Yaffe K., Belfor N., Jagust W.J., DeCarli C., Reed B.R., Kramer J.H., Computer-Based Cognitive Training for Mild Cognitive Impairment: Results from a Pilot Randomized, Controlled Trial Alzheimer Dis Assoc Disord. Author manuscript; available in PMC 2010 Jul 1.Published in final edited form as: Alzheimer Dis. Assoc. Disord. 2009;23(3):205–10.
  13. Corey-Bloom J., Anand R., Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol. 1998;1:55–65.
  14. 14C
  15. Vellas B., Messina J., Hartman R., et al. Multi-dimensionality of treatment benefits in Alzheimer’s disease: investigating the correlation between activities of daily living and cognition in patients treated with rivastigmine. Research and practice in Alzheimer’s disease. Volume 5. Serdi Publishing (Paris). Springer Publishing Company (NY), 2001. P. 193–204.
  16. Преображенская И.С., Громова Д.О. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;10:36–42.
  17. Qaseem A., Snow V., Cross J.T. Jr, Forciea M.A., Hopkins R. Jr, Shekelle P., Adelman A., Mehr D., Schellhase K., Campos-Outcalt D., Santaguida P., Owens D.K. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 2008;148:370–78.
  18. Oertel W., Ross J.S., Eggert K., Adler G. Rationale for transdermal drug administration in Alzheimer’s disease. Neurology. 2007;69:4–9.
  19. Куташов В.А., Самсонов А.С. Комплаентность и качество терапии болезни Альцгеймера при приеме Меманталя. РМЖ. 2014;22:2013–014.
  20. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin.Ther. 2003;25(1):178–93.
  21. Amenta F., Carotenuto A., Fasanaro A.M., et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer’s Disease) Trial: interim results after two years of treatmen. J. Alzheimers Dis. 2014;42(Suppl 3):S281–88.
  22. Parnetti L., Amenta F., Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech. Ageing Dev. 2001;122:2041–55.
  23. Doggrell S.A., Evans S. Treatment of dementia with neurotransmission modulation. Expert Opin. Investig Drugs. 2003;12:1633–54.
  24. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. 2005;(2):CD000269.
  25. Батышева Т.Т., Нестерова О.С., Отческая О.В., Хозова А.А., Зайцев К.С., Камчатнов П.Р., Бойко А.Н. Применение церетона у больных с умеренными когнитивными расстройствами сосудистого генеза. Трудный пациент. 2009;4(7):10–12.
  26. Менделевич Е.Г., Сурженко И.Л., Дунин Д.Н., Богданов Э.И. Церетон в лечении когнитивных нарушений у больных дисциркуляторной и посттравматической энцефалопатией. Российский медицинский журнал. 2009;17(3):2–4.
  27. Камчатнов П.Р., Абусуева Б.А., Евзельман М.А., Есин Р.Г., Кольяк Е.В., Новикова Л.Б., Приказчиков С.В., Рябов А.Г., Умарова Х.Я., Бойко А.Н. Эффективность церетона при остром ишемическом инсульте (результаты исследования СОЛНЦЕ). Журнал неврологии и психиатрии. Инсульт. 2012;3:10–14.
  28. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–943.
  29. Weintraub D., Rosenberg P.B., Drye L.T., Martin B.K., Frangakis C., Mintzer J.E., Porsteinsson A.P., Schneider L.S., Rabins P.V., Munro C.A., Meinert C.L., Lyketsos C.G.; DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am. J. Geriatr. Psychiatry. 2010;18:332–40.

About the Autors

V.A. Parfenov – Doctor of Medical Sciences, Prof., Head of the Department of Nervous Diseases and Neurosurgery SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMPH, Moscow
A.A. Naumenko - Department of Nervous Diseases and Neurosurgery SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMPH, Moscow
I.S. Preobrazhenskaya - Department of Nervous Diseases and Neurosurgery SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMPH, Moscow

Similar Articles

Бионика Медиа